BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AGAH - ECPv5.16.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AGAH
X-ORIGINAL-URL:https://dev.agah.eu
X-WR-CALDESC:Events for AGAH
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20130331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20131027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130411
DTEND;VALUE=DATE:20130413
DTSTAMP:20260929T022347
CREATED:20190310T142821Z
LAST-MODIFIED:20190613T203752Z
UID:3138-1365638400-1365811199@dev.agah.eu
SUMMARY:22nd AGAH Annual Meeting 2013
DESCRIPTION:Joint Conference of European Human Pharmacological Societies \nEARLY CLINICAL UTILITY ASSESSMENT OF NEW MEDICINES IN DEVELOPMENT \n\n\n\n	Announcement \n\n\n  \nDear Colleague \n\n2013 is a special year for CLUB PHASE 1\, as this year itcelebrates its 20th anniversary\, welcoming fellowEuropean colleagues of AGAH\, BAPU and AHPPI to thestunning region of NICE\, where we will join forces tooffer our second joint meeting.\nIt will be a great opportunity to share our views on thechallenges currently being faced by the Early ClinicalDevelopment and Clinical Pharmacology.\nThe meeting will focus on Early Clinical UtilityAssessment of new medicines and how earlydevelopment should be conducted to optimize thechallenging process of reaching efficient and earlygo/no go decisions.\nAfter review of some “historical” cases\, this meeting willupdate attendees on new translational tools andinnovative approaches\, and will highlight the need for astrong presence of European Human Pharmacology inEarly Development.\nWe hope that the plenary lectures and workshops willprovide ample opportunity to discuss ideas\, strategies\,methods\, technology and experience in early clinicaldevelopment. \n\nLooking forward to welcoming you in Sophia Antipolis\,France. \n\nDoctor Yves Donazzolo\nClub Phase 1 President \n\n\n  \n\n\n\n\n	Day 1\, 11 April 2013 \n  \n\n8:00 \nRegistration \n\n8:30 \nWelcome and introduction to the Joint Conference of Club Phase I\, AGAH\, BAPU and AHPPI \n\nSession 1: \n Lessons learned from late phase failures\nand successes \n\nChairs \nY. Donazzolo\, Grenoble (France)\nM. Raghoebar\, Antwerp (Belgium) \n\n8:45 \nLessons learned from Rimonabant and other CB1 blockers: did we try to crack a nut with a sledgehammer?\nR. F. Witkamp\, Wageningen (The Netherlands) \n\n9:15 \nClinical Pharmacology and Clinical Utility of Abiraterone Acetate\nE. Mannaert\, Beerse (Belgium) \n\n9:45 \nThe role of Phase I in the quest for “good” cholesterol – failure of the CETP modulator Dalcetrapib\nM. Derks\, Basel (Switzerland) \n\n10:15 \nBreak \n\nSession 2: \nNew translational tools and methodologies \n\nChairs: \nA. Patat\, Rennes (France)\nM. Hammond\, Slough\, Berkshire (UK) \n\n10:45 \nUsefulness of modeling and simulations in drug development\nE. Pigeolet\, Basel (Switzerland) \n\n11:15 \nPharmacometrics: a new tool for optimizing early drug development in oncology\nR. Gomeni\, La Fouillade (France) \n\n11:45 \nNew biomarkers for drug-induced liver injury: first² insights from clinical quantification\nM. Merz\, Basel (Switzerland) \n\n12:15 \nQuantification of EEG: pre-competitive consortium on the use of EEG as a CNS biomarker\nPh. Danjou\, Paris (France) \n\n12:45 \nLunch Break \n\n14:15 \nParallel Workshops \n\nWS1 \nCardiac safety\, QT assessment\nB. Mendzelevski\, London (UK)\nJ. Taubel\, London (UK) \n\nWS2 \nPK/PD modeling\nR. Gomeni\, La Fouillade (France) \n\nWS3 \nApplication of Bayesian Statistics in early development studies\nP. Sanwald Ducray\, Basel (Switzerland)\nF. Vandenhende\, Genappe (Belgium) \n\nWS4 \nAdaptive study design in early phase clinical research\nM. O’Kane\, London (UK)\nU. Lorch\, London (UK) \n\nWS5.a \nSuicidality assessment\nE. Legangneux\, Basel (Switzerland) \n\n15:45 \nBreak \n\nSession 3: \nTraining and education in early clinical drug development \n\nChairs: \nK. Breithaupt-Grögler\, Frankfurt (Germany)\nJ. de Hoon\, Leuven (Belgium) \n\n16:15 \nEuropean post-graduate training in pharmaceutical medicine and drug development\nI. Klingmann\, Brussels (Belgium) \n\n16:35 \nHuman Pharmacology courses: the UK experience\nJ. Posner\, London (UK) \n\n16:55 \nOpen Forum Discussion: “Diploma-level training for Phase 1 Investigators – need or nice-to-have? \n\n17:15 \nEnd of Sessions on Day 1 \n\n19:30 \nScientific Conference Dinner \n\n\n\n\n	Day 2\, 12 April 2013 \nSession 4: \nInnovative approaches to Proof-of-Concept \n\nChairs: \nJ. Taubel\, London (UK)\nO. van Schoor\, Antwerp (Belgium) \n\n9:00 \nRapid transition from bench to bedside:\nAn overview; what is new\, what has proven its value\, what are the latest trends in translational medicine\nJ. Theis\, Bergisch-Gladbach (Germany) \n\n 9:30  \nNetwork-based drug discovery – rationale\nand successful application to epilepsy\nM. Johnson\, London (UK) \n\n10:00 \nCutting edge developments: biomarker qualification as an indicator for clinical endpoints and their role in setting an optimal biologic dose\nS. Jurcevic\, London (UK) \n\n10:30  \nBreak \n\n11:00 \nParallel Workshops \n\nWS1-WS4 \nRepetition of Day 1 \n\nWS1 \nCardiac safety\, QT assessment\nB. Mendzelevski\, London (UK)\nJ. Taubel\, London (UK) \n\nWS2 \nPK/PD modeling\nR. Gomeni\, La Fouillade (France) \n\nWS3 \nApplication of Bayesian Statistics in early development studies\nP. Sanwald Ducray\, Basel (Switzerland)\nF. Vandenhende\, Genappe (Belgium) \n\nWS4 \nAdaptive study design in early phase clinical\nresearch\nM. O’Kane\, London (UK)\nU. Lorch\, London (UK) \n\nWS5.b \nPain Models\nPh. Danjou\, Paris (France) \n\n12:30 \nLunch Break \n\nSession 5: \nStrengthening European Human Pharmacology for the Early Development of New Medicines \n\nChairs: \nP. Dewland\, Cardiff (UK)\nH. Sourgens\, Munich (Germany) \n\n13:30 \nA critical review of the proposed EU\nClinical Trial regulation\nW. Janssens\, Brussel (Belgium)\nFederal Agency for Medicine and Health Products \n\n14:15 \nNeed for a uniform European registration\nsystem for volunteer participation?\nA. Peremans\, Aalst (Belgium) \n\n15:00  \nRisk adapted approaches and clinical trial notification scheme\nM. O’Kane\, London (UK) \n\n16:00 \nEnd of Conference \n\n\n\n\n\n	Venue \nHotel Sophia Country\n3550 Route des Dolines BP 15\n06410 Biot-Sophia Antipolis (FRANCE)\nPhone: +33 4 92 966878 \n\n\n\n\n	Inquiries \nIntercom Kongresse GmbH\nAntje Blömeke | Matthias Runow\nEppendorfer Baum 39a\n20249 Hamburg (GERMANY)\nPhone/-Telefax: +49 40 480610 -62/ -66\nabloemeke@intercom.de | mrunow@intercom.de\n\n\n\n\n	Fees \n  \n\n\n\nMember of*\n380 €\n\n\nNon-Members\n430 €\n\n\nJunior Scientist\n270 €\n\n\n\n\n*CP1: http://www.clubphase1.com\n*AGAH: http://www.agah.info\n*BAPU: http://www.bapu.be\n*AHPPI: http://www.ahppi.org.uk \nStart Online-Registration and Hotel reservation by\nhttp://l.hh.de/JointConference_2013 \n\n\n\n\n	Downloads \nProgramme of the Annual Meetings 2013\nJointConference2013_3rdAnnouncement
URL:https://dev.agah.eu/event/22nd-agah-annual-meeting-2013/
LOCATION:Annual Meeting 2013\, Nice Sophia Antipolis\, Frankreich
CATEGORIES:Annual Meetings
END:VEVENT
END:VCALENDAR